Innovation Pharmaceuticals Inc (IPIX)

[cellardwellar]

If I was short I'd be very nervous.

2021 American Society of Virology Annual Meeting
July 21, 2021
Antiviral data data related to Brilacidin, the Company’s defensin-mimetic drug candidate, has been accepted for an Oral Presentation at the American Society of Virology’s 40th Annual Meeting (ASV 2021), taking place July 19-23, 2021.

The presentation—“Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as Broad Spectrum Inhibitor of Acutely Infectious Viruses”—is based on ongoing independent laboratory research being conducted by scientists at George Mason University (GMU)/National Center for Biodefense and Infectious Diseases (NCBID).

Brilacidin was shown to exhibit a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, as well as different types of alphaviruses, in cell culture.

Further details on the Brilacidin ASV 2021 presentation will be forthcoming.

Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and has fully enrolled 120 patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients.